COMP <GO>
WRBY vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Warby Parker Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: WRBY 3
— ABBV 10
■ METRIC PARITY
LAST: $24.61 (+0.08%) • MKT CAP: $3.04B
options-implied-move
7.40%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WRBY VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WRBY | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.00% | 70.20% | -16.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -1.70% | 29.00% | -30.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.44% | 3.47% | -2.03 | ABBV | /fcf-yield <GO> |
| Operating Margin | -0.60% | 24.60% | -25.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.20% | 6.90% | -6.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 13.00% | 8.60% | +4.40 | WRBY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.35 | 5.33 | +0.02 | WRBY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | WRBY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.40% | 7.40% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.9 | 72.8 | -26.85 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.14 | 1.15 | -0.01 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 113.1x | +26.90 | ABBV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.04B | $513.86B | -$510.82B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WRBY REV | ABBV REV | WRBY GROSS % | ABBV GROSS % | WRBY FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $871.9M | $61.16B | 54.0% | 70.2% | $43.7M | $17.82B |
| FY 2024 | $771.3M | $56.33B | 55.3% | 70.0% | $34.7M | $17.83B |
| FY 2023 | $669.8M | $54.32B | 44.0% | 44.0% | $30.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WRBY // BETA 1.14
ABBV // BETA 1.15